IP Library Granted Patent US 8,729,022
Granted Patent B2
US 8,729,022 · App. 13/573,310 · Granted May 20, 2014

Stabilised solid compositions of factor VII polypeptides

Inventors: Michael Bech Jensen (Allerod, DK); Birthe Lykkegaard Hansen (Vaerloese, DK); Troels Kornfelt (Virum, DK)
Assignee: Novo Nordisk Healthcare AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,729,022
App. No.
13/573,310
Granted
May 20, 2014
Kind
B2
Abstract

The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.

Claims (41)

1. A composition comprising a Factor VII polypeptide;

about 0.1 to 5 mg/ml of an antioxidant;

about 5 to 20 mg/ml of a saccharide;

and about 10 to 40 mg/ml of a polyol, said composition having a moisture content of not more than about 3%, wherein

said Factor VII polypeptide is wild type human Factor VII or a polypeptide exhibiting substantially the same or improved biological activity relative to wild type human Factor VII.

2. The composition according to claim 1 , wherein the antioxidant is selected from the group consisting of homocysteine, cysteine, cystathionine, methionine, gluthatione, and peptides containing any one of homocysteine, cysteine, cystathionine, methionine, and gluthatione.

3. The composition according to claim 1 , wherein the saccharide is selected from the group consisting of sucrose, dextrose, lactose, maltose, trehalose, cyclodextrins, maltodextrins and dextrans.

4. The composition according to claim 1 , wherein the polyol is selected from the group consisting of mannitol, sorbitol and xylitol.

5. The composition according to claim 1 , wherein the composition is stable such that not more than about 5% w/w of the initial content of Factor VII polypeptide is converted to aggregates upon storage of said composition at 30° C. for 8 months.

6. The composition according to claim 1 , wherein the composition is stable such that not more than about 6% w/w of the initial content of Factor VII polypeptide is converted to oxidised forms upon storage of said composition at 30° C. for 8 months.

7. The composition according to claim 1 , further comprising an agent suitable for keeping the pH of said composition in the range of 3 to 9 when dissolved in aqueous solvent.

8. The composition according to claim 7 , wherein said agent is selected from the group consisting of citrate, acetate, histidine, malate, phosphate, tartaric acid, succinic acid, MES, HEPES, PIPES, imidazol, TRIS, lactate, glutamate and glycylglycine.

9. The composition according to claim 1 , further comprising a tonicity modifier.

10. The composition according to claim 9 , wherein the tonicity modifier is selected from the group consisting of sodium acetate, sodium lactate, sodium chloride, potassium chloride and calcium chloride.

11. The composition according to claim 1 , further comprising a surfactant.

12. The composition according to claim 11 , wherein the surfactant is selected from the group consisting of polysorbates; polyoxyethylene alkyl ethers; poloxamers; ethylene/polypropylene block polymers; and polyethyleneglycols (PEGs).

13. The composition according to claim 1 , further comprising one or more other pharmaceutical excipients acting as a bulking agent.

14. The composition according to claim 1 , wherein the saccharide is sucrose.

15. The composition according to claim 1 , wherein the polyol is mannitol.

16. The composition according to claim 1 , wherein the Factor VII Polypeptide is selected from the group consisting of Human Factor VIIa and a Factor VII Sequence Variant.

17. The composition according to claim 16 , wherein the Factor VII Polypeptide is recombinant human Factor VIIa.

18. The composition according to claim 1 , wherein the Factor VII Polypeptide is a Factor VII-related polypeptide and wherein the ratio between the activity of said Factor VII-related polypeptide and wild-type Factor VII is at least 1.25 when tested in an in vitro proteolysis assay or in an in vitro hydrolysis assay.

19. The composition according claim 16 , wherein Factor VII polypeptide is present in a concentration of from about 0.6 mg/ml to about 10.0 mg/ml.

20. The composition according to claim 1 , wherein said moisture content is not more than about 2.5% w/w.

21. The composition according to claim 1 , wherein the composition is a lyophilised cake.

22. The composition according to claim 11 , wherein the surfactant is selected from the group consisting of a polysorbate and a poloxamer.

23. The composition according to claim 1 , wherein the antioxidant is methionine.

24. The composition according to claim 1 , further comprising L-histidine.

25. The composition according to claim 1 , further comprising one or more components selected from the group consisting of: CaCl 2 , NaCl, and Glycylglycine.

26. A composition according to claim 1 wherein

Factor VII is 1 mg/ml;

mannitol is 25 mg/ml;

sucrose is 10 mg/ml;

and methionine is 0.5 mg/ml.

27. A composition according to claim 26 ,

further comprising 10 mM CaCl2.

28. The composition according to claim 26 , wherein

Factor VII is 1 mg/ml;

mannitol is 25 mg/ml;

sucrose is 10 mg/ml; and

methionine is 0.5 mg/ml.

Assignments (1)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Nov 15, 2021
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 058122/0546 →
Priority Claims (1)
DK 2002 00963 · Jun 21, 2002 · national
Continuity (5)
Continuation 11526503 · Sep 25, 2006
Continuation 10609780 · Jun 30, 2003
Continuation PCTDK0300419 · Jun 20, 2003
Provisional Application 60394153 · Jul 3, 2002
Related Publication 20130017184A1 · Jan 17, 2013